Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995125 | 0.84 | RAB9A (0.53) | NPC1LMNAHTTGAAHSD17B10 | |
| SCHEMBL6991334 | 0.84 | KCNMA1 (0.57) | NPC1LMNATP53GAAHSD17B10 | |
| SCHEMBL7666549 | 0.83 | MAPT (0.49) | NPC1LMNAHTTTP53HSD17B10 | |
| SCHEMBL7661723 | 0.82 | HDAC1 (0.43) | NPC1LMNAGAAKDM4EALDH1A1 | |
| SCHEMBL6998631 | 0.82 | KCNMA1 (0.61) | NPC1LMNAHTTTP53GAA | |
| SCHEMBL7654114 | 0.82 | CXCR2 (0.51) | NPC1LMNAHTTKDM4EHPGD | |
| SCHEMBL6996991 | 0.82 | KCNMA1 (0.52) | NPC1LMNAGAAKDM4EALDH1A1 | |
| SCHEMBL7663393 | 0.81 | KCNMA1 (0.45) | NPC1LMNAHTTTP53HSD17B10 | |
| SCHEMBL7665120 | 0.80 | MAPT (0.50) | NPC1LMNAHTTTP53GAA | |
| SCHEMBL7664430 | 0.79 | KDM4E (0.48) | NPC1LMNAGAAHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1016664-B1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6455521-B1 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| CN-1268949-A | Fused thiophene compounds and medical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-1016664-A1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | ACIN1, ACHE, TPMT | NPC1 465/4885LMNA 4763/4885HTT 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.